Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Leap Therapeutics (NASDAQ:LPTX) announced it will present final clinical results from Part B of the DeFianCe Phase 2 study at the ESMO Congress 2025. The study evaluates sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, combined with bevacizumab and chemotherapy versus a control arm in advanced microsatellite stable (MSS) colorectal cancer patients.
The presentation will be delivered by Dr. Zev A. Wainberg from UCLA in a Mini Oral Session on October 19, 2025 at 4:05 p.m. CEST in Berlin, Germany. The study focuses on second-line therapy for MSS colorectal cancer patients who have received one prior systemic therapy.
Leap Therapeutics (NASDAQ:LPTX) ha annunciato che presenterà i risultati clinici finali della Parte B dello studio DeFianCe Phase 2 all'ESMO Congress 2025. Lo studio valuta sirexatamab (DKN-01), un anticorpo monoclonale anti-DKK1, in combinazione con bevacizumab e chemioterapia rispetto a un braccio di controllo in pazienti con cancro colorettale avanzato MSS.
La presentazione sarà tenuta dal Dott. Zev A. Wainberg dell'UCLA in una Mini Oral Session il 19 ottobre 2025 alle 16:05 CEST a Berlino, in Germania. Lo studio si concentra sulla terapia di seconda linea per i pazienti MSS colangiocarcinoma? No, correggiamo: per i pazienti MSS del colon-retto che hanno ricevuto una precedente terapia sistemica.
Leap Therapeutics (NASDAQ:LPTX) anunció que presentará los resultados clínicos finales de la Parte B del estudio DeFianCe Phase 2 en el Congreso ESMO 2025. El estudio evalúa sirexatamab (DKN-01), un anticuerpo monoclonal anti-DKK1, en combinación con bevacizumab y quimioterapia frente a un brazo de control en pacientes con cáncer colorrectal metastásico avanzado MSS.
La presentación será realizada por el Dr. Zev A. Wainberg de la UCLA en una Mini Oral Session el 19 de octubre de 2025 a las 16:05 CEST en Berlín, Alemania. El estudio se centra en la terapia de segunda línea para pacientes con cáncer colorrectal MSS que han recibido una terapia sistémica previa.
Leap Therapeutics (NASDAQ:LPTX)은 ESMO Congress 2025에서 DeFianCe 2상 연구의 파트 B의 최종 임상 결과를 발표할 예정이라고 발표했다. 연구는 sirexatamab (DKN-01), DKK1에 대한 항체를 bevacizumab 및 화학요법과 함께 사용하며 MSS로 알려진 진행성 대장암 환자에서 대조군과 비교한다.
발표는 UCLA의 Zev A. Wainberg 박사가 2025년 10월 19일 오후 4:05 CEST에 베를린(독일)에서 열리는 Mini Oral Session에서 진행된다. 연구는 이전에 하나의 전신 치료를 받은 MSS 대장암 환자의 2차 치료에 초점을 맞춘다.
Leap Therapeutics (NASDAQ:LPTX) a annoncé qu'il présentera les résultats cliniques finaux de la partie B de l'étude DeFianCe Phase 2 au congrès ESMO 2025. L'étude évalue le sirexatamab (DKN-01), un anticorps monoclonal anti-DKK1, en association avec bevacizumab et une chimiothérapie par rapport à un bras témoin chez des patients atteints d'un cancer colorectal avancé MSS.
La présentation sera assurée par le Dr Zev A. Wainberg de l'UCLA lors d'une Mini Oral Session le 19 octobre 2025 à 16h05 CEST à Berlin, Allemagne. L'étude se concentre sur le traitement de seconde ligne chez les patients MSS atteint de cancer colorectal qui ont reçu une thérapie systémique préalable.
Leap Therapeutics (NASDAQ:LPTX) gab bekannt, dass es Endgültige klinische Ergebnisse aus Teil B der DeFianCe Phase-2-Studie beim ESMO-Kongress 2025 präsentieren wird. Die Studie bewertet Sirexatamab (DKN-01), einen anti-DKK1-Monoklonalantikörper, in Kombination mit Bevacizumab und Chemotherapie gegenüber einer Kontrollgruppe bei fortgeschrittenem MSS-Darmkrebs.
Die Präsentation wird von Dr. Zev A. Wainberg von der UCLA in einer Mini Oral Session am 19. Oktober 2025 um 16:05 CEST in Berlin, Deutschland, gehalten. Die Studie konzentriert sich auf die Zweitlinienbehandlung bei MSS-Darmkrebs-Patienten, die eine vorherige systemische Therapie erhalten haben.
Leap Therapeutics (NASDAQ:LPTX) أعلنت أنها ستعرض النتائج السريرية النهائية من الجزء B من دراسة DeFianCe المرحلة الثانية في مؤتمر ESMO 2025. الدراسة تقيم sirexatamab (DKN-01)، جسم مضاد أحادي النسيلة موجه ضد DKK1، بالكشف مع bevacizumab وكيمياء الأدوية مقارنة بذراع تحكم لدى مرضى سرطان القولون والمستقيم المتقدم MSS.
سيقدم العرض الدكتور زيف A. وينبرغ من جامعة كاليفورنيا في لوس أنجلوس UCLA في جلسة شفهية مصغرة Mini Oral Session يوم 19 أكتوبر 2025 في الساعة 4:05 مساءً بتوقيت وسط أوروبا (CEST) في برلين، ألمانيا. يركز البحث على العلاج من الدرجة الثانية لمرضى MSS المصابين بسرطان القولون والمستقيم الذين تلقوا علاجًا جهازيًا واحدًا سابقًا.
Leap Therapeutics（NASDAQ:LPTX）宣布将在ESMO大会2025上展示DeFianCe II期研究Part B的最终临床结果。该研究评估 sirexatamab（DKN-01），一种抗-DKK1单抗，与贝伐单抗及化疗联合使用，与对照组相比用于晚期 MSS 结直肠癌患者。
此次报告将由 UCLA 的 Zev A. Wainberg 博士 在德国柏林举行的 Mini Oral Session 于 2025年10月19日 CEST 16:05 进行。该研究聚焦于对已接受过一次全身治疗的 MSS 结直肠癌患者的二线治疗。
- None.
- None.
Mini Oral Session Details:
Title: DeFianCe Trial: A randomized phase 2 trial of sirexatamab (DKN-01) plus bevacizumab and chemotherapy versus bevacizumab and chemotherapy as second-line therapy in advanced microsatellite stable (MSS) colorectal cancer (CRC)
Presenter: Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of the GI Oncology Program at UCLA
Session Type: Mini Oral Session
Session Category: GI Tumours, Lower Digestive
Date and Time: Sunday, October 19, 2025, 4:05 p.m. CEST
Location: Cologne Auditorium – CityCube A
Abstract Number: LBA34
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), a humanized monoclonal antibody targeting the Dickkopf-1 (
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.
All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's plan to reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; and (iv) the availability of strategic alternatives that would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-final-clinical-data-from-part-b-of-the-defiance-study-at-the-esmo-congress-2025-302566702.html
SOURCE Leap Therapeutics, Inc.
FAQ
What will Leap Therapeutics (LPTX) present at ESMO Congress 2025?
When and where will LPTX present the DeFianCe study results?
What is sirexatamab (DKN-01) and how is it being studied by LPTX?
Who will present Leap Therapeutics' DeFianCe trial results at ESMO 2025?
